A Phase 1, open-label, multiple-dose study of KHK4827 in subjects with systemic sclerosis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2018
At a glance
- Drugs Brodalumab (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kyowa Hakko Kirin
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.
- 12 Sep 2017 New trial record